Trial Search Results

Feasibility Study for GORE® TAG® Thoracic Branch Endoprosthesis to Treat Proximal Descending Thoracic Aortic Aneurysms

The purpose of this study is to assess the feasibility of the use of the GORE® TAG® Thoracic Branch Endoprosthesis to treat aneurysms involving the proximal Descending Thoracic Aorta (DTA)

Stanford is currently accepting patients for this trial.

Lead Sponsor:

W.L.Gore & Associates

Stanford Investigator(s):


  • Device: Branched TAG® Device




Inclusion Criteria:

   1. Presence of DTA aneurysm deemed to warrant surgical repair which requires proximal
   graft placement in Zone 2:

      1. Fusiform (≥ 55 mm), or

      2. Fusiform (>2 times native aortic diameter), or

      3. Saccular (no diameter criteria)

   2. Age ≥18 years at time of informed consent signature

   3. Subject is capable of complying with protocol requirements, including follow-up

   4. Informed Consent Form (ICF) is signed by Subject or legal representative

   5. Must have appropriate proximal aortic landing zone, defined as:

      1. Must require coverage of the left subclavian artery (LSA) origin for exclusion of
      the lesion

      2. Aortic inner diameters between 16-48 mm

      3. Landing zone, which must include the LSA ostium, cannot be aneurysmal, heavily
      calcified, or heavily thrombosed,

      4. Acceptable proximal landing zone outer curvature length for the required device

      5. Landing zone must be native aorta

   6. Must have appropriate distal aortic landing zone, defined as:

      1. Outer curvature length must be ≥2cm proximal to the celiac artery

      2. Aortic inner diameters between 16-48mm (diameter should be between 16-42mm if
      using distal TAG® Device extension)

      3. Landing zone cannot be aneurysmal, heavily calcified, or heavily thrombosed

      4. Native aorta or previously implanted GORE® TAG® Device

   7. Must have appropriate LSA landing zone, defined as:

      1. LSA length of ≥3 cm proximal to first major branch vessel if using Aortic
      Component with 8 mm portal diameter, or LSA length of ≥2.5 cm proximal to first
      major branch vessel if using Aortic Component with 12 mm portal diameter

      2. LSA inner diameters of 6-15 mm if using Aortic Component with 8 mm portal
      diameter, or inner diameters of 11-18 mm if using Aortic Component with 12 mm
      portal diameter

      3. Target branch vessel landing zone cannot be aneurysmal, heavily calcified, or
      heavily thrombosed

Exclusion Criteria:

   1. Concomitant aneurysm/disease of the ascending aorta, aortic arch, or abdominal aorta
   requiring repair

   2. Previous endovascular repair of the ascending aorta

   3. Previous endovascular repair of the DTA with a non-Gore device

   4. Surgery within 30 days of treatment

   5. Infected aorta

   6. Dissection of the DTA

   7. Intramural hematoma of the DTA without DTA aneurysm

   8. Life expectancy <2 years

   9. Myocardial infarction or stroke within 6 weeks prior to treatment

10. Patient has a systemic infection and may be at increased risk of endovascular graft

11. Pregnant female at time of informed consent signature

12. Degenerative connective tissue disease, e.g. Marfan's or Ehler-Danlos Syndrome

13. Participation in another drug or medical device study within one year of study

14. Known history of drug abuse within one year of treatment

15. Significant thrombus or atheroma in the aortic arch

16. Tortuous or stenotic iliac and/or femoral arteries preventing introducer sheath
   insertion and the inability to use a conduit for vascular access

17. Planned coverage of left carotid or celiac arteries

18. Patient has known sensitivities or allergies to the device materials

19. Patient has known hypersensitivity or contraindication to anticoagulants or contrast
   media, which is not amenable to pre-treatment

20. Previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or known
   hypersensitivity to heparin

21. Diameter taper outside of the device sizing range between proximal and distal landing
   zones of aorta and the inability to use additional devices of different diameters to
   compensate for the taper

22. Mycotic aneurysm

23. Persistent refractory shock (systolic blood pressure <90 mm Hg)

24. Patient has body habitus or other medical condition which prevents adequate
   visualization of the aorta

   Additionally, the following exclusion criteria apply for Subjects enrolled in Stage 1:

25. Aberrant right subclavian or left vertebral arteries

26. Occluded/stenosed/hypoplastic right vertebral artery

27. Presence of a patent left internal mammary artery (LIMA) graft

28. Bilateral carotid artery disease

29. Known incomplete Circle of Willis

30. Known left vertebral artery ending in posterior inferior cerebellar artery (PICA)

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305